BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of
Share
Why It Matters
BlossomHill partnered with Foundation Medicine to create a special test. This test helps doctors find which patients might benefit from their new medicine.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.